Table 5.
Summary of clinicopathologic characteristics of patients with ALK-rearranged NSCLC and clinical activity of crizotinib in patients enrolled in the first in-human trial (PROFILE 1001) over a period of 4 years
aMean.
Abbreviations: CI, confidence interval; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, not reported; PFS, progression-free survival; ORR, overall response rate; SD, stable disease.